Bradley Herring Sells 4,134 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN - Get Free Report) CFO Bradley Herring sold 4,134 shares of Enfusion stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $41,877.42. Following the sale, the chief financial officer now owns 266,369 shares in the company, valued at approximately $2,698,317.97. This represents a 1.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Bradley Herring also recently made the following trade(s):

• On Friday, December 20th, Bradley Herring sold 24,443 shares of Enfusion stock. The stock was sold at an average price of $10.61, for a total transaction of $259,340.23.

Enfusion Price Performance

Shares of NYSE:ENFN traded down $0.32 during mid-day trading on Friday, hitting $9.97. The company had a trading volume of 351,791 shares, compared to its average volume of 403,182. The firm has a fifty day moving average price of $10.11 and a 200 day moving average price of $9.19. The company has a market capitalization of $1.28 billion, a PE ratio of 249.31, a price-to-earnings-growth ratio of 3.98 and a beta of 0.95. Enfusion, Inc. has a one year low of $7.52 and a one year high of $11.38.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Stifel Nicolaus boosted their price target on shares of Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. Piper Sandler boosted their price target on shares of Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research report on Monday, December 23rd. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $10.25.

Institutional Trading of Enfusion

Hedge funds have recently modified their holdings of the stock. Arizona State Retirement System bought a new stake in Enfusion during the 2nd quarter valued at $86,000. Harbor Capital Advisors Inc. increased its stake in Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company's stock valued at $113,000 after purchasing an additional 1,315 shares in the last quarter. Belvedere Trading LLC bought a new stake in Enfusion during the 3rd quarter valued at $114,000. Paloma Partners Management Co bought a new stake in Enfusion during the 3rd quarter valued at $157,000. Finally, The Manufacturers Life Insurance Company increased its stake in Enfusion by 27.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company's stock valued at $167,000 after purchasing an additional 4,239 shares in the last quarter. Institutional investors own 81.05% of the company's stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.